Cargando…

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review

Proprotein convertase subtilisin/kexin type 9 (PCSK9), one of the key regulators of the low-density lipoprotein receptor (LDLR), can play a direct role in atheroma development. Although advances in the understandings of genetic PCSK9 polymorphisms have enabled to reveal the role of PCSK9 in the comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gianazza, Erica, Macchi, Chiara, Banfi, Cristina, Ruscica, Massimiliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291627/ https://www.ncbi.nlm.nih.gov/pubmed/37378405 http://dx.doi.org/10.3389/fcvm.2023.1191303

Ejemplares similares

Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity
por: Macchi, Chiara, et al.
Publicado: (2022)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
por: Dozio, Elena, et al.
Publicado: (2020)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells
por: Macchi, Chiara, et al.
Publicado: (2021)

PCSK9 induces a pro-inflammatory response in macrophages
por: Ricci, Chiara, et al.
Publicado: (2018)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Macrophage Phenotyping in Atherosclerosis by Proteomics
por: Eligini, Sonia, et al.
Publicado: (2023)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Lipidomics unveils the complexity of the lipidome in metabolic diseases
por: Lydic, Todd A., et al.
Publicado: (2018)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells
por: Greco, Maria Francesca, et al.
Publicado: (2022)

Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges
por: Gianazza, Erica, et al.
Publicado: (2023)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
por: Kamaruddin, Nurjannatul Naim, et al.
Publicado: (2021)

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis
por: Gualtierotti, Roberta, et al.
Publicado: (2023)

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale
por: Kostapanos, Michael S., et al.
Publicado: (2019)

Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics
por: Gianazza, Erica, et al.
Publicado: (2020)

Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure
por: Brioschi, Maura, et al.
Publicado: (2021)

Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study
por: Ruscica, Massimiliano, et al.
Publicado: (2023)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

Brain-Derived Neurotrophic Factor and Extracellular Vesicle-Derived miRNAs in an Italian Cohort of Individuals With Obesity: A Key to Explain the Link Between Depression and Atherothrombosis
por: Amadio, Patrizia, et al.
Publicado: (2022)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Proteomics of Extracellular Vesicles: Update on Their Composition, Biological Roles and Potential Use as Diagnostic Tools in Atherosclerotic Cardiovascular Diseases
por: Mallia, Alice, et al.
Publicado: (2020)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion
por: Chen, Xiao-Wei, et al.
Publicado: (2013)

SUN-580 PCSK9 and Lp(a): Association Between PCSK9 Level and Larger Apo(a) Isoform Size in African-Americans and Caucasians
por: Byambaa, Enkhmaa, et al.
Publicado: (2020)

Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials
por: Luo, Jichang, et al.
Publicado: (2022)

A lipidomic analysis approach to evaluate the response to cholesterol-lowering food intake
por: Szymańska, Ewa, et al.
Publicado: (2011)

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study
por: Cacciottolo, Paul J, et al.
Publicado: (2021)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
por: Xia, Xiao-dan, et al.
Publicado: (2021)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?
por: Ying, Qidi, et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Protocol to evaluate the impact of murine MCT1-deficient CD8(+) T cells on adipogenesis
por: Macchi, Chiara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_litm7jb3h7ik6j2qe6k2fvbg8d